BOSTON, Mass., April 13, 2023 — Constant Therapy Health, a next generation digital therapeutics company, today announced that it has been issued a new U.S. Patent by the United States Patent and Trademark Office (USPTO), further solidifying its position as a leader in the field of AI-powered therapeutics. This marks the third patent secured by Constant Therapy Health in relation to its proprietary NeuroPerformance Engine, a revolutionary system that delivers targeted and customized therapy activities to over 550,000 users through advanced AI-powered technology.
Constant Therapy Health’s NeuroPerformance Engine utilizes an AI-powered core to analyze real-world user data and deliver evidence-based, personalized cognitive, language, and speech therapy to patients. The company’s patented technology provides a user-responsive, adjustable system through which the Constant Therapy app delivers individualized digital therapy.
The newly issued patent covers specific aspects of the company’s NeuroPerformance Engine, focusing on its proprietary technology which harnesses AI to compare a patient’s performance in the Constant Therapy App with that of patients who have similar conditions. The NeuroPerformance Engine then leverages that information to deliver customized speech and cognitive therapy activities to users.
In addition to the new patent for its NeuroPerformance Engine, Constant Therapy Health today also announced that it is incorporating Generative AI (the technology behind ChatGPT) to deliver therapy to patients.
These tandem milestones underscore Constant Therapy Health’s industry-leading commitment to incorporating the latest developments in artificial intelligence into its technology, empowering the company to consistently deliver cutting-edge therapy to users around the world through an engaging, personalized, and cost-effective experience.